Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
AIMS: Elevated non-fasting triglycerides mark elevated levels of remnant cholesterol. Using a Mendelian randomization approach, we tested whether genetically increased remnant cholesterol in hypertriglyceridaemia due to genetic variation in the apolipoprotein A5 gene (APOA5) associates with an increased risk of myocardial infarction (MI). METHODS AND RESULTS: We resequenced the core promoter and coding regions of APOA5 in individuals with the lowest 1% (n = 95) and highest 2% (n = 190) triglyceride levels in the Copenhagen City Heart Study (CCHS, n = 10 391). Genetic variants which differed in frequency between the two extreme triglyceride groups (c.-1131T > C, S19W, and c.*31C > T; P-value: 0.06 to <0.001), thus suggesting an effect on triglyceride levels, were genotyped in the Copenhagen General Population Study (CGPS), the CCHS, and the Copenhagen Ischemic Heart Disease Study (CIHDS), comprising a total of 5705 MI cases and 54 408 controls. Genotype combinations of these common variants associated with increases in non-fasting triglycerides and calculated remnant cholesterol of, respectively, up to 68% (1.10 mmol/L) and 56% (0.40 mmol/L) (P < 0.001), and with a corresponding odds ratio for MI of 1.87 (95% confidence interval: 1.25-2.81). Using APOA5 genotypes in instrumental variable analysis, the observational hazard ratio for a doubling in non-fasting triglycerides was 1.57 (1.32-2.68) compared with a causal genetic odds ratio of 1.94 (1.40-1.85) (P for comparison = 0.28). For calculated remnant cholesterol, the corresponding values were 1.67(1.38-2.02) observational and 2.23(1.48-3.35) causal (P for comparison = 0.21). CONCLUSION: These data are consistent with a causal association between elevated levels of remnant cholesterol in hypertriglyceridaemia and an increased risk of MI. Limitations include that remnants were not measured directly, and that APOA5 genetic variants may influence other lipoprotein parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Observational cohorts demonstrate that higher TG and remnant cholesterol predict cardiovascular events independently of LDL-C, while Mendelian randomization analyses confirm a causal relationship between lifelong TRL elevation and ASCVD.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [62]
In the citing paper
“Epidemiological and Mendelian randomization studies have also pointed toward a causal role of elevated triglycerides in atherosclerosis due to an elevation of remnant cholesterol particles (7-9).”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Elevated triglycerides are associated with an increase in remnant cholesterol, a decrease in high-density lipoprotein cholesterol (HDL-C), and an increase in LDL particles with a change in morphology to small, dense particles.”
From 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia (2021) · cites this paper as [8]
In the citing paper
“Recent systematic studies comparing fasting and non-fasting samples have suggested that the difference is small for most lipid parameters [85,94-100].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [94]
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [76]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Antman, E., Bassand, J.-P., Klein, W., Ohman, M., Lopez Sendon, J. L., Rydén, L., Simoons, M., & Tendera, M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00804-4 · Cited by 4,821
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 1×
“Causal genetic estimates from instrumental variable analysis were compared with an observed risk of MI from observational epidemiology using the Altman and Bland method.(29)”
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Research works printed but not linked: 1
- 2001, Type III hyperlipoproteinemia (dyslipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 2835
Cited by
Items 401–500 of 506
Molecular Genetics of Hypertriglyceridaemia
Dron, J. S., & Hegele, R. A. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0026710 · Cited by 2
Does lowering triglycerides reduce cardiovascular risk?
de Moura, J. P. (2019) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2019.11.005 · Cited by 2
Bery, K., Alherk, M. A., Yahia, M. A. M. K., & Govindankutty, K. (2022) · Scholars Journal of Applied Medical Sciences · doi:10.36347/sjams.2022.v10i05.008 · Cited by 2
Xi, H., Zhang, B., Sun, T., Zhang, J., & Lv, H. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2403071 · Cited by 1
Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00004-2 · Cited by 1
Self-citationKong, L., Yang, Z.-B., Chen, X., Quan, X., Liu, H., & Qiu, A.-P. (2024) · Medicine · doi:10.1097/md.0000000000039595 · Cited by 1
Симонова, Г. И., Щербакова, Л. В., Malyutina, S. K., Каширина, А. П., & Ragino, Y. I. (2024) · Ateroscleroz · doi:10.52727/2078-256x-2024-20-3-326-344 · Cited by 1
Hypertriglyceridemia (> 150 mg/dL) as a marker of cardiovascular risk
López-Miranda, J. (2025) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.500822 · Cited by 2
Liu, N., Zeng, H., Cai, X., Yang, S., Chen, X., Jiang, G., Yuan, J., Cai, J., & Zhou, H. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1654501 · Cited by 1
Bubnova, M. G., Ezhov, M. V., Aronov, D. M., Galyаvich, A. S., Gurevich, V. S., Duplyakov, D. V., Zafiraki, V. K., Karamnova, N. S., Kashtalap, V. V., Konovalov, G. A., et al. (2025) · Cardiosomatics · doi:10.17816/cs688224 · Cited by 1
Qiao, L., Miao, J., Du, W., Liu, Y., Chen, Y., Xu, K., Wang, C., & Chen, H. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1688715 · Cited by 1
Andrade, V. C., Rezende, P. C., Hueb, W. A., Garcia, R. M. R., de Assis, A. C. R., da Silva, M. F., Ribeiro, M. D. O. L., Mocha, M. R., Tairova, M. S., Ramires, J. A. F., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02027-6 · Cited by 1
Hu, Q., Chen, L., Xing, L., Xu, Y., Xiong, J., & Tang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1720189 · Cited by 1
Zhou, L., Yu, P., Li, L., Zhang, J., Long, H., Yu, H., Gu, X., & Hua, H. (2026) · Journal of Investigative Medicine · doi:10.1177/10815589261425968 · Cited by 1
Mahmeed, W. M. A., Al-Kindi, M., Al-sarraf, A., Amin, H., Zirie, M. A., Alawadi, F., Sabbour, H. M., Al-Waili, K., Lessan, N. G., Tikriti, A. A., et al. (2026) · Angiology · doi:10.1177/00033197261422789 · Cited by 2
Zhou, X., Liang, Y., Zhang, J., Nuerbiya, Y., Aihaiti, T., & Wei, H. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113102 · Cited by 1
Association between remnant cholesterol and peripheral artery disease from multiple perspectives
Meng, W., Wang, C., Xu, Z., Qiu, Z., Wang, H., Gu, Y., & Zhu, T. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120784 · Cited by 2
Chapman, M. J., Thérond, P., & Meikle, P. J. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109050 · Cited by 1
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · Praxis · doi:10.1024/1661-8157/a002760 · Cited by 1
Dyslipidemia and Cardiovascular Risk in Obesity
Arca, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-09045-0_12 · Cited by 2
Hypertriglyceridemia, remnant cholesterol and cardiovascular risk: what genes can say
Kei, A. A., & Elisaf, M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12762 · Cited by 1
How important are triglycerides as risk factors?
D’Addato, S., Palmisano, S., & Borghi, C. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000438 · Cited by 1
Fettstoffwechselstörungen: Diagnostik und Therapie
Sinning, D., & Landmesser, U. (2017) · Herz · doi:10.1007/s00059-017-4601-2 · Cited by 2
Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?
COPPLE, T. M., & Ciffone, N. A. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526627.04268.80 · Cited by 1
Saeed, A., Nambi, V., & Jones, P. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54835-9.00005-3 · Cited by 2
Rohatgi, A. K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42880-4.00008-x · Cited by 1
INNOVATIONS IN DIAGNOSTICS AND TREATMENT OF PATIENTS WITH HYPERTRIGLYCERIDEMIA
Симерзин, В. В., Fatenkov, O. V., Gagloeva, I. V., Galkina, M. A., Panisheva, Y. A., & Krasovskaya, M. A. (2017) · Science and Innovations in Medicine · doi:10.35693/2500-1388-2017-0-1-43-51 · Cited by 2
Skoczyńska, A., Wawrzynowicz‐Syczewska, M., Barlik-Rysa, M., Danik, A., Różański, J., Filipiak, K. J., & Cybulska, B. (2020) · Folia Cardiologica · doi:10.5603/fc.2020.0001 · Cited by 1
Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids)
Evans, M. C., & Miller, M. J. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_15 · Cited by 2
Bases genéticas de las hipertrigliceridemias
Candás‐Estébanez, B., Padró‐Miquel, A., & Esteve-Luque, V. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.03.003 · Cited by 2
Increased atherosclerosis in a mouse model of glycogen storage disease type 1a
Rose, A. M. L., Groenen, A. G., Halmos, B., Bazioti, V., Rutten, M. G. S., Krishnamurthy, K. A., Koster, M. H., Kloosterhuis, N., Smit, M., Havinga, R., et al. (2022) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2022.100872 · Cited by 1
Chang, Y.-H., Lin, D.-Y., Tsai, C.-L., Liang, C.-H., Yu, Y., Hsieh, Y., Chuang, J.-Y., Chen, Y., Yeh, H., & Lin, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm13010068 · Cited by 1
Sheikhy, A., Fallahzadeh, A., Sadeghian, S., Pashang, M., Karimi, A., Bagheri, J., Ahmadi‐Tafti, H., & Hosseini, K. (2023) · Clinical Cardiology · doi:10.1002/clc.24132 · Cited by 1
Yang, Z., Chen, H., Lai, F., Zhang, J., Wang, S., Wang, S., Chen, Y., Mai, Z., Luo, L., Kong, D., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1322244 · Cited by 1
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Castañer, O., Ros, E., Pintó, X., Ortega, E., & Fitó, M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.010 · Cited by 1
Nsiah, P., Acquah, S., Bockarie, A. S., Adjei, G., Aniakwaa-Bonsu, E., Togbe, E., Ossei, P. P. S., & Debrah, O. (2023) · Research Square · doi:10.21203/rs.3.rs-2696463/v1 · Cited by 1
Li, L., Chou, V. H. C., Chou, O. H. I., Roy, S., Chan, J. S. K., Wong, W. T., Liu, T., Lip, G. Y. H., Cheung, B. M. Y., Tse, G., et al. (2024) · medRxiv · doi:10.1101/2024.02.08.24302507 · Cited by 1
Targeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Johansen, C. T., MacDonald, A., & Hegele, R. A. (2013) · Wiley eBooks · doi:10.1002/9780470015902.a0025307
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Patient mit schwerstem Chylomikronämiesyndrom
Fischer, S., & Julius, U. (2016) · CardioVasc · doi:10.1007/s15027-016-1028-2
Interplay between lipoproteins, the complement system and blood cells in atherosclerosis
Klop, B. (2014) · Leiden Repository (Leiden University)
Landmesser, U., Gohlke, H., Hambrecht, R., Kelm, M., Laufs, U., & Marx, N. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0166-9 · Cited by 3
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
Hypertriglyceridemia and Remodeling of the Left Ventricle in Patients with Chronic Kidney Disease
Murkamilov, I. (2018) · Journal of Urology & Nephrology Studies · doi:10.32474/juns.2018.01.000115
High-Dose Omega-3 Fatty Acids in Cardiovascular Prevention: Finally Living Up to Their Potential?
Nelson, A. J., Mirzaee, S., & Nicholls, S. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00363-3
How ApoB Measurements Could Improve Prevention of Cardiovascular Disease
Sniderman, A. D. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_29
Anderson, J. L. C. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.192996734
Remnant Cholesterol and Ischemic Cardiovascular Disease: A Cross-Sectional Study in Northern ChinaPreprint
Liu, M., Zhang, N., Fang, X., Bao, H., Yan, T., Zhu, H., Zhao, Y., Zhang, W., Bi, Y., Tian, Z., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1140711/v1
Wang, G., Wang, J., Wang, Y., An, Y., Liu, J., & Leng, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1286214/v1
Quispe, R., Das, T. M., & Michos, E. D. (2021) · Springer eBooks · doi:10.1007/978-3-030-75055-8_2
Obesity and Dyslipidemia, Importance of Body Fat Distribution
Karpe, F. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch11
Wang, K., Ding, Y., Gao, W. Y., Wang, R., Yang, J., Liu, X., Shen, H., & Ge, H. (2021) · Research Square · doi:10.21203/rs.3.rs-664372/v1
Zhao, Q., Zhang, T., Cheng, Y., Ma, Y., Xu, Y.-K., Yang, J., & Zhou, Y. (2020) · doi:10.21203/rs.3.rs-33302/v1
Zhang, S.-L., Du, X., Xu, J. Q., Xiang, Q., & Liu, L. (2020) · Research Square · doi:10.21203/rs.3.rs-60051/v1
Dyslipidemic and Protective Effects of Aspirin and Clopidogrel in Obese Rats
Anwar, I. D. (2018) · International Journal of Pharmaceutical Sciences and Research · doi:10.13040/ijpsr.0975-8232.9(9).3647-55 · Cited by 1
Lee, J. Y., Lee, D., Yoo, N. Y., & Lee, H. J. (2022) · Korean Journal of Family Practice · doi:10.21215/kjfp.2022.12.3.167
Triglyceride-Rich Lipoproteins
Bazarbashi, N., & Miller, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_12
Coronary Artery Calcium-Based Approach to Lipid Management
Kole, A., & Joshi, P. H. (2022) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-022-00704-z
Har HDL-kolesterol og triglyserider en rolle i hjerte- og karsykdom?
Christensen, J. J. (2015) · Norsk tidsskrift for ernæring · doi:10.18261/ntfe.13.4.7 · Cited by 1
Genetic lipid disorders, the APOE gene and Familial Dysbetalipoproteinemia
Heidemann, B. E. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1408
Athanasopoulou, E., & Protogerou, A. D. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.021
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_8
Self-citationYang, X. H., Zhang, B. L., & Jin, H. M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.06.968
Guan, B., Wang, A., & Xu, H. (2023) · Figshare · doi:10.6084/m9.figshare.23930438
Impact of Rare and Common Genetic Variants on Lipoprotein Metabolism
Motazacker, M. M., Kastelein, J. J. P., & Kuivenhoven, J. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00006-2
Bai, J., Dong, Z., Zhang, L., Li, S., Chen, R., Di, J., Wang, W., Wu, Y., & Zhou, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4367440/v1
Josipović, J., Jelaković, A., Morić, B. V., Prelević, V., Mirošević, G., Matijaca, H., Ivanko, I., Bulj, N., Gabrić, I. D., & Jelaković, B. (2024) · Preprints.org · doi:10.20944/preprints202406.0451.v1
The Impact of Remnant Cholesterol on Cardiovascular Fitness in Young Adults: Insights from NHANESPreprint
Qin, S., Chen, J., Sun, M., & Zhang, D. (2024) · Research Square · doi:10.21203/rs.3.rs-4517007/v1
Triglyceride Levels Should be Lowered to Reduce Cardiovascular Risk
Corral, P., & Cobo, A. L. (2025) · Revista Argentina de Cardiología · doi:10.7775/rac.v93.i1.20865
Medicina Personalizada: Genética e Inovações no Tratamento de Doenças
PRAXEDES, M. F. S., & Aragao, J. A. (2025) · Editora Científica Digital eBooks · doi:10.37885/978-65-5360-978-5
IMPLICAÇÕES DAS VARIANTES GENÉTICAS PARA A MEDICINA DE PRECISÃO NA HIPERTRIGLICERIDEMIA
Gama, G. Q., Soares, L. A., Barcelos, E. C. S., & Errera, F. I. V. (2025) · Editora Científica Digital eBooks · doi:10.37885/250218915
Galatius, E. S., Lassen, M. C. H., Skaarup, K. G., Johansen, N. D., Galatius, S., Jensen, G. B., Schnohr, P., Møgelvang, R., & Biering‐Sørensen, T. (2025) · Echocardiography · doi:10.1111/echo.70249
The “SMART” side of hypertriglyceridemia
Cabezas, M. C., & Klop, B. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120467
Taheri, R., Weaver, O. R., Ye, M., Vena, J. E., Johnson, J. A., Vine, D. F., Eurich, D. T., & Proctor, S. D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1630126
Malkani, K. V., Zhang, R., Sobti, N. K., Vadaketh, K., Groenendyk, J., Purkayastha, S., Ying, X., Newbury, D., Steitieh, D., Patel, S. A., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101318
Taheri, R., Weaver, O. R., Krysa, J. A., Vine, D. F., Khoury, M., & Proctor, S. D. (2025) · CJC Pediatric and Congenital Heart Disease · doi:10.1016/j.cjcpc.2025.10.006 · Cited by 1
Lu, X., Liang, H., Zhou, X., Wu, Y., Sha, L., & Lei, H. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s563873
Yexuan, C., Zhang, H.-W., Jin, J.-L., Liu, H.-H., Zhang, Y., Gao, Y., Guo, Y.-L., Wu, N.-Q., Hua, Q., Li, Y.-F., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12618338
Guan, B., Wang, A., & Xu, H. (2023) · Figshare · doi:10.6084/m9.figshare.23930435
Hu, X., Lin, Y., Appleton, A. A., Wang, W., Yu, B., Zhou, L., Li, G., Zhou, Y., Ou, Y., & 董豪坚 (2024) · Figshare · doi:10.6084/m9.figshare.26692126
Zhao, M., Xiao, M., Tan, Q., Ji, J., & Lu, F. (2024) · Figshare · doi:10.6084/m9.figshare.25034463
Guan, B., Wang, A., & Xu, H. (2023) · Figshare · doi:10.6084/m9.figshare.23930429
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Figshare · doi:10.6084/m9.figshare.14905926
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Figshare · doi:10.6084/m9.figshare.14905929
Chen, S., Xu, Y., Chen, B., Lin, S., Lu, L., MinNa, C., Wang, Y., Yang, Q., Ling, S., Zhou, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25389512
Qi, W., Jiang, F., Bai, S.-B., Zhang, Y., Fang, Z.-H., Zhou, Y.-S., Chen, R. R., Zhang, Z.-H., Wang, L., Li, W., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1638134
Zhao, H., Zhang, Z., Zhang, Y., Jiang, W., Qi, C., Ren, L., & CHEN, S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1782646
Rafiei, Z., Dehghan, P., Aliasgharzadeh, S., Yagin, N. L., & Asghari-Jafarabadi, M. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107238
Wang, J., Jin, Y., Wang, L., Wang, Y., & Lu, J. (2026) · International Journal of General Medicine · doi:10.2147/ijgm.s604377
Hypertriglyceridemia in adults with diabetes mellitus in Korea: Sex, age, and lifestyle determinants
Park, K., Hong, S., Kim, K. W., Han, K., & Park, C.-Y. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.04.025
Li, Y., Chen, Z., Shang, L., Wang, Y., Liu, X. R., Yang, Y., & He, L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1770876
Zhou, K., Liu, G., Zhang, B., Zhang, X., Wu, W., & Wu, S. L. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02992-5
Бубнова, М. Г., Владиславович, Е. М., Dm, A., Сарварович, Г. А., Савельевич, Г. В., Дупляков, Д. В., Зафираки, В. К., Станиславовна, К. Н., Васильевич, К. В., Александрович, К. Г., et al. (2025) · Cardiosomatics
Liu, Y., Xuesong, L., Yan, W., Sun, R., Yu, Y., Chen, A., Dong, Z., Li, X. T., & Lv, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1785669
Sun, M., Huang, R., Gao, W., Jia, X., Han, M., Miao, Y., Ning, N., Zhou, W., Wang, X., Hang, D., et al. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109091
Metadata
- Authors
- Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A.
- Affiliations
- University of Copenhagen (DK)
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-17
- Volume
- 34
- Issue
- 24
- Pages
- 1826-1833
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2040770080
- Cited by
- 501
- References
- 60
- Citations by year
- 2026: 28 · 2025: 53 · 2024: 48 · 2023: 40 · 2022: 51 · 2021: 45 · 2020: 41 · 2019: 39 · 2018: 26 · 2017: 34 · 2016: 31 · 2015: 30 · 2014: 20 · 2013: 11
- FWCI
- 19.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- remnant cholesterol, hypertriglyceridemia, myocardial infarction, APOA5, genetic variants, causal risk factors, remnant lipoproteins, Copenhagen City Heart Study, Copenhagen General Population Study, instrumental variables, Mendelian randomization
- MeSH terms
- Apolipoprotein A-V, Adult, Aged, Aged, 80 and over, Apolipoproteins A, Cholesterol, Female, Genotype, Humans, Lipoproteins, Male, Middle Aged, Myocardial Infarction, Promoter Regions, Genetic, Prospective Studies, Risk Factors, Triglycerides, Hypertriglyceridemia, Linkage Disequilibrium, Case-Control Studies, Polymorphism, Single Nucleotide, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.